Respiratory inhaler devices are essential tools for delivering medication directly into the lungs for the treatment and ...

The toxic haze that blanketed large parts of India in November didn’t just cloud the skies—it pushed sales of asthma and COPD medicines to their highest levels in three years.

Deepens partnership with COPD Foundation to drive patient awareness and engagement Building on nine decades of 'Caring for Life' globally and ten years of impact in the U.S., Cipla continues to ...

Pharmaceutical major Cipla Ltd has inked a deal to acquire Inzpera Healthsciences Ltd to expand its portfolio of paediatric drugs and wellness products. Mumbai-listed Cipla said it will fully acquire ...

Drugmaker Cipla Limited is set to acquire 100 per cent stake in Inzpera Healthsciences Limited, a subsidiary of Tata Industries, for an estimated Rs 110 crore. The acquisition will strengthen Cipla’s ...

Gupta joined Cipla in 2021 and has been in his current role since February Cipla's global chief executive and managing director, Umang Vohra, will step down at the end of March after almost a decade ...

Pharma major Cipla Ltd reported a steady performance for the second quarter ended September 30, 2025. Image Credit: Canva Cipla Share Price: Pharma major Cipla Ltd reported a steady performance for ...

Cipla Health is aggressively expanding its health and wellness offerings. The company aims for ₹1,500 crore revenue by FY26. This growth will be driven by creating new product categories, strategic ...

Cipla is betting big on its partnership with Eli Lilly to commercialize tirzepatide, the blockbuster diabetes and weight-loss drug sold globally under the brand name Mounjaro, as it seeks to deepen ...

Indian multinational pharmaceutical giant Cipla witnessed a decline of more than 4% in its shares during the intraday trading session on Thursday, 30 October 2025. The fall followed the announcement ...

Cipla Q2 FY26 Results: The India business generated Rs 3,146 crore in revenue, up 7 per cent YoY, led by solid traction in core therapies. Cipla’s respiratory brand Foracort retained its No. 1 ranking ...

Global CEO & MD Umang Vohra to step down in March end Global COO Achin Gupta to take over Cipla should focus on innovation over next 5-to-7 years - Vohra Beats second-quarter profit view Oct 30 ...